CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Differential Effects of Drug-Eluting Stents on Local Endothelium-Dependent Coronary Vasomotion
Michalis I. Hamilos, MD*,
Miodrag Ostojic, MD, PhD ,
Branko Beleslin, MD, PhD,
Dragan Sagic, MD, PhD ,
Ljubco Mangovski, MD,
Sinisa Stojkovic, MD, PhD,
Milan Nedeljkovic, MD, PhD,
Dejan Orlic, MD,
Bratislav Milosavljevic, MD,
Dragan Topic, MD,
Nevena Karanovic, MD, PhD ,
William Wijns, MD, PhD*,* on behalf of the NOBORI CORE Investigators
* Cardiovascular Centre, Aalst, Belgium
Department of Cardiology, University Institute for Cardiovascular Diseases, Clinical Center of Serbia, Belgrade, Serbia
Institute for Cardiovascular Disease Dedinje, Belgrade, Serbia
Ministry of Health of Serbia, Belgrade, Serbia.
Manuscript received October 8, 2007;
revised manuscript received November 20, 2007,
accepted December 8, 2007.
* Reprint requests and correspondence: Dr. William Wijns, Cardiovascular Center Aalst, OLV Clinic, Moorselbaan, 164, B-9300 Aalst, Belgium. (Email: William.Wijns{at}village.uunet.be).
Objectives: The aim of our study was to compare coronary vasomotion after implantation of a second-generation biolimus A9-eluting stent (BES) and of a sirolimus-eluting stent (SES).
Background: Drug-eluting stents (DES) have been associated with impaired local coronary vasomotion, delayed endothelialization, and increased late thrombotic risk. New DES with different drugs, pharmacokinetics, and polymers have been developed.
Methods: Nineteen patients with a BES and 15 patients with a SES were studied 9 months after stent implantation. Endothelium-dependent and -independent coronary vasomotion were tested proximally and distally to the stent as well as at a reference segment during right atrial pacing at increasing heart rates. Quantitative coronary angiographic measurements were performed offline.
Results: Of the patients with BES, 2 showed vasoconstriction with increased heart rate and 17 showed vasodilatation. Of the patients with a SES, 9 showed vasoconstriction while 6 showed vasodilatation. The SES showed significant vasoconstriction at both the proximal (–2.3 ± 10% vs. 7.9 ± 10%) and the distal (–5.4 ± 9% vs. 6.1 ± 8%) segments to the stent compared with the BES (p = 0.003 for proximal, p < 0.001 for distal segment). Endothelium-independent vasomotion after intracoronary nitrates did not differ significantly between the 2 groups (p = NS for proximal and distal segment).
Conclusions: Unlike the case with the SES, endothelium-dependent vasomotion at adjacent stent segments seems to be preserved after BES implantation. This result may be explained by the different drug release kinetics, DES design, or characteristics of polymer used in the stent system.
|
Abbreviations and Acronyms
| | BES = biolimus A9-eluting stent(s) | | DES = drug-eluting stent(s) | | PES = paclitaxel-eluting stent(s) | | QCA = quantitative coronary angiography | | SES = sirolimus-eluting stent(s) |
|
Related Articles
-
Endothelial Dysfunction Associated With Drug-Eluting Stents: What, Where, When, and How?
- Joseph B. Muhlestein
J. Am. Coll. Cardiol. 2008 51: 2139-2140.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A29-A30.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S.-i. Hayashi, A. Yamamoto, F. You, K. Yamashita, Y. Ikegame, M. Tawada, T. Yoshimori, S. Shimizu, and S. Nakashima
The Stent-Eluting Drugs Sirolimus and Paclitaxel Suppress Healing of the Endothelium by Induction of Autophagy
Am. J. Pathol.,
November 1, 2009;
175(5):
2226 - 2234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hamilos, O. Muller, T. Cuisset, A. Ntalianis, G. Chlouverakis, G. Sarno, O. Nelis, J. Bartunek, M. Vanderheyden, E. Wyffels, et al.
Long-Term Clinical Outcome After Fractional Flow Reserve-Guided Treatment in Patients With Angiographically Equivocal Left Main Coronary Artery Stenosis
Circulation,
October 13, 2009;
120(15):
1505 - 1512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Byrne, A. Kastrati, S. Kufner, S. Massberg, K. A. Birkmeier, K.-L. Laugwitz, S. Schulz, J. Pache, M. Fusaro, M. Seyfarth, et al.
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial
Eur. Heart J.,
October 2, 2009;
30(20):
2441 - 2449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2080 - 2097.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chevalier, S. Silber, S.-J. Park, E. Garcia, G. Schuler, H. Suryapranata, J. Koolen, K. E. Hauptmann, W. Wijns, M.-C. Morice, et al.
Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberte Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial--Phase 2
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
188 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Kim, H. S. Seo, J. H. Park, J. O. Na, C. U. Choi, H. E. Lim, E. J. Kim, S.-W. Rha, C. G. Park, and D. J. Oh
A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction.
J. Am. Coll. Cardiol.,
May 5, 2009;
53(18):
1653 - 1659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hamilos, J. Sarma, M. Ostojic, T. Cuisset, G. Sarno, N. Melikian, A. Ntalianis, O. Muller, E. Barbato, B. Beleslin, et al.
Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses
Circ Cardiovasc Interv,
December 1, 2008;
1(3):
193 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Muhlestein
Endothelial dysfunction associated with drug-eluting stents what, where, when, and how?
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2139 - 2140.
[Full Text]
[PDF]
|
|
|
|
